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Background: Oral migalastat has recently been approved for the treatment of Anderson-Fabry disease (FD) in
patients aged ≥16 years with amenable mutations on the basis of two phase III trials, FACETS and ATTRACT.
However, with the introduction of migalastat into clinical practice, it is important to correctly identify the patients
who may gain the most benefits from this therapy. Due to the relatively recent availability of migalastat, its role in
clinical practice still has to be included in guidelines or recommendations. On these bases, a multidisciplinary group
of Italian Experts in the treatment of FD has run the GALA project, with the aim to collect the opinions of expert
physicians and to propose some starting points for an experience-based use of migalastat.
Results: Overall, although studies and data from longer-term follow-up with migalastat are still emerging, available
evidence is consistent in showing that this molecule does represent a suitable therapy for the treatment of FD, in
patients aged ≥16 years and with amenable mutations. The use of migalastat as an oral option appears to be
overall safe, and experience thus far indicates potential for improving quality of life, controlling GI symptoms,
stabilizing renal function and reducing cardiac hypertrophy.
Conclusion: Migalastat can be considered either as a first-line therapy – given its efficacy, extensive tissue
penetration, convenient oral regimen, and the current limited therapeutic options available – or in patients on
enzyme-replacement therapy (ERT) who experience side effects, with poor compliance to chronic i.v. therapy, or
with clinical evidence of progression of the disease.
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Anderson-Fabry disease (FD) is a X-linked lysosomal dis-
order, due to deficiency of the enzyme α-galactosidase
caused by mutations in the GLA gene (located on the long
arm of the X chromosome at Xq22). This deficiency leads
to the progressive accumulation of lysosomal glycosphin-
golipids, particularly globotriaosylceramide (GL-3) [1–4].
The accumulation of these substrates causes multiorgan
damage and may eventually lead to major complications,© The Author(s). 2020 Open Access This artic
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opathy and cerebrovascular events, with an increased risk
of premature death [3, 4]. Cardiac arrhythmias, including
conduction abnormalities, supraventricular and ventricu-
lar tachyarrhythmias can be the first clinical manifestation
of the disease and can occur also in absence of hyper-
trophic cardiomyopathy [5].
FD is a relatively rare condition. Indeed, neonatal screen-
ing programs have reported with varying incidences of this
condition, ranging from 1/1250 to 1/7800 in newborn
males, although it has been observed that the later-
onset phenotype of FD is underdiagnosed, making the
incidence of a-Gal A deficiency 15–20-times higherle is distributed under the terms of the Creative Commons Attribution 4.0
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damage in different organs and systems, the therapeutic
approach to patients with this condition should ideally be
multidisciplinary and integrated within an individualized
plan [4, 9]. Early initiation of therapy is crucial and con-
tributes to optimize clinical outcomes [4]. Enzyme re-
placement therapy (ERT) has been approved in the
treatment of FD since 2001 [10]. This approach also re-
mains effective over a long-term period [4]; however, it is
associated with some potential drawbacks including in-
complete tissue penetration and reduced compliance due
to a complex administration scheme [1, 11, 12]. Lastly,
ERT likely has no proven effect on stroke and white mat-
ter lesion occurrence [13].
Migalastat (1-deoxygalactonojirimycin) is an analogue
of the terminal galactose of GL-3; it is a pharmacological
chaperone that stabilizes and facilitates trafficking of
amenable mutant forms of the α-galactosidase A enzyme
from the endoplasmic reticulum to lysosomes; in this
site, dissociation of migalastat allows α-galactosidase to
catabolize accumulated substrates [14, 15].
Oral migalastat administration has recently been approved
for the treatment of FD in patients aged ≥16 years with
amenable mutations on the basis of two phase III trials,
FACETS and ATTRACT [15–17]. With the introduction of
migalastat into clinical practice, it is important to correctly
identify the patients who may gain the most benefits [4].
Due to the relatively recent availability of migalastat,
its role in clinical practice has only been included in
Canadian guidelines and is still to be considered for
European recommendations [18].
On these bases, a multidisciplinary group of Italian
Experts in the treatment of FD has run the GALA
project, with the aim to collect the opinions of expert
physicians and to propose an experience-based use of
migalastat.
The GALA project: overall architecture
The GALA project was initiated by a group of expert
physicians on the treatment of FD and consisted of
three different phases. In the first phase, the Expert
Panel, composed of seven Experts from different back-
grounds (cardiology, nephrology, neurology) with well-
documented experience in the management of FD, as
assessed by a number of international peer-reviewed
publications, gathered and, with the help of a profes-
sional facilitator, elaborated a questionnaire aimed to
evaluate the degree of consensus on the diagnosis and
management of FD. The questionnaire was then admin-
istered to other Italian clinicians (n = 20, including the
members of the GALA Working Group) with wide ex-
perience in the treatment of FD. The responses to the
questionnaire were collected by an online system and
analyzed by a dedicated provider (Springer Healthcare).The results were then shared and discussed during a sec-
ond meeting, where both the Expert Panel and the Work-
ing Group were present. The results were extensively
discussed with the help of the professional facilitator.
Experience-based recommendations on the use of migala-
stat were retrieved from the statements and reformulated
until a consensus was reached.
The questionnaire
The questionnaire consisted of two different sections,
namely: (i) a descriptive section (12 items), aimed at describ-
ing the management of FD, ERT, and migalastat; and (ii) an
analytic section (20 items), which evaluated migalastat ther-
apy in different clinical scenarios. This latter section repre-
sented the basis for the definition of the recommendations.
The questionnaire is reported in Table 1.
Each item of the questionnaire was presented to define
the degree of agreement on a precise statement, accord-
ing to a 5-point Likert scale (1 = strongly disagrees, 2 =
disagrees, 3 = neither agrees or disagrees, 4 = agrees, 5 =
strongly agrees). In the analysis of data, the threshold for
consensus was set at 75% of responders who agreed or
strongly agreed upon a statement.
Overview of the results
All the invited experts answered all items of the ques-
tionnaire. Table 1 summarizes the results of the voting:
overall, a consensus was reached on the majority of
items (26/32). A comment on each single item of the
questionnaire goes beyond the scope of this article.
The experience-based recommendations
The replies to the analytical phase were used to draft ten
experience-based recommendations, which were then
grouped according to the scenario they depict. Those
statements are listed in Table 2 and commented in the
following paragraphs.
Migalastat: role in the therapy of FD
• According to current evidence, migalastat is an effective and generally
well tolerated treatment for FD in patients with amenable pathogenic
mutations.
• The use of oral therapy with migalastat can improve the quality
of life of patients with FD.
• In a male patient aged ≥16 years with amenable mutations and
type 1 classic FD, migalastat may also be considered at diagnosis
when signs/symptoms of organ damage are not present.
• In a male patient aged ≥16 years with amenable mutations and
type 2 late-onset FD, migalastat may also be considered at
diagnosis at the presence of signs and symptoms of organ damage.
• In a female patient aged ≥16 years, with amenable mutations and
type 1 classic or type 2 late-onset FD, migalastat can be considered
at the presence of early signs/symptoms of organ involvement.
Table 1 The questionnaire on the management of Fabry disease (FD) (questions #1–12) and the use of migalastat (questions #13–32),









1 The therapeutic goal for FD is the prevention and/or
stabilization of organ damage
0 0 100
2 In a patient with FD and progressive organ damage,
the main therapeutic goal is the control of symptoms
and the long-term stabilization of clinical status
0 0 100
3 The impact on QoL is an important parameter in the
management of a patient with FD
0 0 100
4 ERT is effective on most symptoms in FD 5 25 70
5 ERT is effective on organ damage in FD 10 20 70
6 Administration of ERT by i.v. route can be a limitation
to daily activities in patients with FD
0 15 85
7 Potential immunogenicity of therapy can represent a
limitation of ERT
0 20 80
8 Early initiation of treatment could improve the prognosis
of patients with FD
0 5 95
9 When compared with i.v., oral therapy can improve QoL
in patients with FD
0 5 95
10 According to available data, migalastat can be considered
a safe and effective treatment for FD
0 0 100
11 According to available evidence, one of the advantages
of migalastat over ERT is its superior efficacy on heart
damage
0 30 70
12 Poor compliance to oral therapy with migalastat can be
an issue
35 35 30
13 Migalastat therapy can be taken into consideration as an
alternative to ERT in patients with FD and amenable mutations
0 0 100
14 In a male patient aged ≥16 years with amenable mutations
and classic FD, migalastat therapy might be taken into
consideration at diagnosis, even when signs/symptoms of
organ damage are lacking
20 15 65
15 In a male patient aged ≥16 years with amenable mutations
and classic FD, migalastat therapy is recommended in the
presence of signs/symptoms of organ damage
5 15 80
16 In a male patient aged ≥16 years with amenable mutations
and non-classic FD, migalastat therapy is recommended in
the presence of signs/symptoms of organ damage
0 15 85
17 In a female patient aged ≥16 years with amenable mutations
and classic FD, migalastat therapy might be taken into
consideration at diagnosis, even when signs/symptoms of
organ damage are lacking
45 20 35
18 In a female patient aged ≥16 years with amenable mutations
and classic FD, migalastat therapy is recommended in the
presence of signs/symptoms of organ damage
0 10 90
19 In a female patient aged ≥16 years, amenable mutation and
non-classic FD, migalastat therapy could be taken into
consideration at the first onset of signs/symptoms of organ
damage
0 0 100
20 Migalastat therapy is recommended in patients with FD
aged ≥16 years, with amenable mutations and heart
hypertrophy (≥11mm)
0 5 95
21 Migalastat treatment should be taken into consideration in
patients aged ≥16 years with FD, amenable mutations and
rhythm disorders (sinus bradycardia, atrial fibrillation, extrasystole)
and/or ECG alterations
0 20 80
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Table 1 The questionnaire on the management of Fabry disease (FD) (questions #1–12) and the use of migalastat (questions #13–32),









22 Migalastat therapy is recommended in patients with FD
aged ≥16 years with amenable mutations and pathological
microalbuminuria (according to KDIGO guidelines)
0 10 90
23 Migalastat therapy is recommended in patients with FD
aged ≥16 years with amenable mutations and proteinuria
(according to KDIGO guidelines)
0 10 90
24 Migalastat therapy is recommended in patients aged ≥16 years
with FD, amenable mutations and eGFR 60–90ml/min/1,73m2
(CKD-EPI) with evidence of progression of decline of renal
function (> −1 ml/min/1,73m2/year)
0 15 85
25 Migalastat therapy is recommended in patients aged ≥16 years
with FD, amenable mutations and eGFR 30–60ml/min/1,73m2
(CKD-EPI)
0 20 80
26 Migalastat treatment could be taken into consideration in
patients aged ≥16 years with FD, amenable mutations and
progression of white matter lesions
5 10 85
27 Migalastat treatment should be taken into consideration in
patients aged ≥16 years with FD, amenable mutations and
history of TIA/stroke
0 10 90
28 Migalastat treatment should be taken into consideration in
patients aged ≥16 years with FD, amenable mutations and
progressive loss of hearing (corrected by age)
10 10 80
29 Migalastat treatment should be taken into consideration in
patients aged ≥16 years with FD, amenable mutations and
gastrointestinal symptoms
0 20 80
30 Migalastat treatment should be taken into consideration in
patients aged ≥16 years with FD, amenable mutations and
acroparesthesia, even if controlled by symptomatic therapy
5 15 80
31 In a patient aged ≥16 years and amenable mutations, already
in therapy with ERT, switching to migalastat should be taken
into consideration in the case of unstable disease and/or poor
response
0 10 90
32 In a patient aged ≥16 years and amenable mutations, already
in therapy with ERT, switching to migalastat should be taken
into consideration in the case of uncontrolled infusion reactions
and/or poor compliance to i.v. therapy
0 0 100
eGFR estimated glomerular filtration rate, ECG electrocardiogram, ERT enzyme replacement therapy, FD Fabry disease, i.v. intravenous, KDIGO Kidney Disease
Improving Global Outcomes, QoL quality of life, TIA transient ischemic attack
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with broad tissue distribution in multiple organs. It binds
selectively and reversibly to the active sites of amenable
mutant forms of α-galactosidase A enzyme. This high-
affinity binding allows migalastat to stabilize the enzyme
in the endoplasmic reticulum and facilitate proper traf-
ficking to lysosomes. Once in lysosomes, migalastat disso-
ciates from α-galactosidase A, allowing the breakdown of
substrates [1].
A preliminary experience with migalastat is worth
mentioning. In a pooled analysis of two phase II studies
in males with FD, migalastat decreased urinary GL-3 by
≥20% in five out of six patients with amenable muta-
tions, and serum levels remained overall unchanged [19].
GL-3 content was decreased in renal biopsies of fourpatients and skin biopsies of three patients with amen-
able mutations.
The clinical efficacy of migalastat has then been evaluated
in the two pivotal phase III trials. The randomized, double-
blind, placebo controlled, phase III FACETS study was con-
ducted in ERT-naïve males and females (aged 16–74 years)
with FD and amenable mutations [17]. Patients were ran-
domly assigned to receive either migalastat 150mg every
other day (n = 34) or placebo (n = 33) for 6months,
followed by open-label migalastat for a further 6months;
patients could then participate in a 12-month open-label
extension. Among the randomized patients, 50 (74.6%)
were considered as amenable to migalastat based on the
validated GLP HEK (Good Laboratory Practice human
embryonic kidney) assay, which identifies GLA variants
with the potential to respond to migalastat [20]. A 3.0%
Table 2 Expert-based recommendations on the use of
migalastat in Fabry disease (FD)
According to current evidence, migalastat is an effective and generally
well tolerated treatment for FD in patients with amenable pathogenic
mutations.
The use of oral therapy with migalastat can improve the quality of life
of patients with FD.
In a male patient aged ≥16 years with amenable mutations and type 1
classic FD, migalastat may also be considered at diagnosis when signs/
symptoms of organ damage are not present.
In a male patient aged ≥16 years with amenable mutations and type
2 late-onset FD, migalastat may also be considered at diagnosis at the
presence of signs and symptoms of organ damage.
In a female patient aged ≥16 years, with amenable mutations and
type 1 classic or type 2 late-onset FD, migalastat can be considered
at the presence of early signs/symptoms of organ involvement.
Treatment with migalastat can be considered in patients with FD
aged ≥16 years with amenable mutations, and heart hypertrophy
and/or rhythm alterations and/or ECG alterations.
Treatment with migalastat can be considered in patients with FD aged
≥16 years with amenable mutations and persistent microalbuminuria,
and/or proteinuria and/or eGFR 30–90ml/min/1.73m2
Treatment with migalastat can be considered in patients with FD
aged ≥16 years with amenable mutations and transient ischemic
attack /stroke and/or white matter lesions.
Treatment with migalastat can be considered in patients with FD
aged ≥16 years with amenable mutations with acroparaesthesia,
and/or gastrointestinal symptoms, and/or hearing loss.
In a patient aged ≥16 years with amenable mutation already in
treatment with ERT, switching to migalastat should be considered
in the case of unstable patients and/or uncontrolled infusion
reactions and/or poor compliance to intravenous therapy.
eGFR estimated glomerular filtration rate, ERT enzyme replacement therapy, FD
Fabry disease
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indicating that increases of 1 to 5% of normal enzyme activ-
ity in vivo may be clinically meaningful [16].
These patients were included in the modified intent-to-
treat (mITT) population used for post hoc efficacy analyses.
While, with the ITT analysis, a numerically higher response
rate was observed in the proportion of patients with ≥50%
reduction in number of GL-3 inclusions per kidney intersti-
tial capillary at 6months (primary endpoint) with migala-
stat compared to placebo, the post hoc analysis on the
mITT population demonstrated that migalastat was associ-
ated with a significantly greater reduction in the mean
number of KIC GL-3 inclusions compared to placebo
(− 0.25 ± 0.10 vs 0.07 ± 0.13; p = 0.008). In addition,
the KIC GL-3 reduction remained stable for a further
6 months of treatment in the migalastat group, and
the number of inclusions was reduced from 6 to 12
months in patients who switched from placebo to
migalastat (− 0.33 ± 0.15 vs 0.01 ± 0.04; p = 0.01).
On the other hand, the randomized, open-label, phase
III ATTRACT study included ERT-experienced patients
aged 16–74 years, with FD and amenable mutation as
assessed by the GLP HEK assay [15]. Patients wereassigned to either continuation of ERT (n = 19) or switch-
ing to migalastat 150mg QOD (n = 34) for 18months; pa-
tients could then receive open-label migalastat for 12
months. Overall, migalastat and ERT had comparable ef-
fects on renal function: the mean annualised eGFRCKD-EPI
from baseline to month 18 was − 0.40 ± 0.93 (− 2.27 to
1.48) mL/min/1.73m2/year for migalastat vs. − 1.03 ± 1.29
(− 3.64 to 1.58) mL/min/1.73m2/year for ERT. The pro-
portion of patients who experienced renal, cardiac, or
cerebrovascular events was also similar with migalastat
and ERT (29% vs 44%; p = 0.36). Patient-reported scores
on the Brief Pain Inventory Short-Form-Pain Severity
Component remained stable in both groups.
The baseline assessment of disease severity in ATTRACT
was comparable with that reported for the Fabry Outcomes
Survey (FOS) and Fabry Registry, and the majority of
subjects had a classical phenotype, so that data from
ATTRACT may be indirectly compared to results of
clinical trials on ERT [21–23]. In addition, by evaluating
patients in the FACETS trial by phenotype, it was observed
that migalastat provided clinical benefit to patients with
Fabry disease and amenable variants, regardless of disease
severity [24].
We also mention that, as further discussed in the
following paragraphs, data from a real-life study found
that the renal function decline was not changed by 1-
year treatment with migalastat [25]. So, patients started
on oral therapy as first-line treatment should be followed
with extra care as to detect poor renal response.
With respect to safety, in the FACETS study, most
adverse events (AEs) were mild-to-moderate. The most
frequently reported AEs with migalastat during the first 6
months of treatment were headache (35%) and nasophar-
yngitis (18%); the incidence of headache decreased to 14%
during months 6–12. No serious migalastat-related AEs
were reported [17]. After 18months of treatment in the
ATTRACT trial, the most frequently reported treatment-
emergent AEs with migalastat were nasopharyngitis (33%)
and headache (25%); these events occurred in 33 and 24%
of patients assigned to ERT, respectively. No serious AE
was considered to be migalastat-related [15].
Based on these results, migalastat was approved for
the treatment of FD in patients aged ≥16 years with
amenable mutations, and is thought to have potential
for an improvement of patients management. Indeed, it has
been shown that the effectiveness of ERT in preventing
renal, cardiac and neurologic complications is limited,
and patients tend to show signs of disease progression
over time [26]. Thus, effective treatment options, such
as migalastat, appear crucial to address this unmet
need. In particular, several features of migalastat could
make this molecule an attractive treatment option.
First, oral administration may be more attractive for
the majority of patients compared to the intravenous
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dosing schedule has been shown to provide a sustained
increase of α-galactosidase A level and migalastat is not
expected to lead to the formation of anti-agalsidase anti-
bodies [19]. Both of these attributes could increase treat-
ment efficacy. Lastly, migalastat is expected, according to
current and emerging evidence, to have better effects on
cardiac outcomes and gastrointestinal symptoms than
ERT, potentially improving both patient morbidity and
quality of life. It should be acknowledged that further
studies are required to investigate the long-term benefits
of migalastat therapy, while some evidence is present for
sustained activity of ERT to slow the decline in estimated
glomerular filtration rate, and reduce/stabilize left ven-
tricular mass and cardiac wall thickness [27].
Patients with cardiac involvement
Treatment with migalastat can be considered in patients with FD aged
≥16 years with amenable mutations, and heart hypertrophy and/or
rhythm alterations and/or ECG alterations.Cardiac involvement in FD is common both in
homozygous males and in heterozygous females and
contributes substantially to disease-related morbidity and
mortality. Moreover, the heart can be mainly involved in
late-onset disease with specific genetic variants associated
with residual enzymatic activity [28].
Cell GB3 accumulation leads to myocardial ischemia,
valvular abnormalities, conduction tissue disease,
arrhythmias, and myocardial hypertrophy. In particular, left
ventricular hypertrophy (LVH) mimics the morphological
and clinical picture of hypertrophic cardiomyopathy [29,
30], with early diastolic dysfunction and preserved ejection
fraction until the end stage of the disease. Cardiac
involvement characterized by early myocardial sphingolipid
storage can be timely detected before overt LVH by cardiac
MRI with T1 mapping [31].
In patients with FD, therapeutic goals are to reduce
morbidity and mortality related to cardiac complications
by early treatment with disease-specific therapies and
conventional supportive therapy according to general
cardiologic guidelines [4].
In the FACETS trial, a significant decrease in mean
LVMi was observed from baseline up to 24 months (−
7.7 g/m2; 95% CI: − 15.4 to − 0.01), with a trend towards
further reduction in patients with LVH at baseline [17].
A decrease in the end-diastolic interventricular septum
thickness was also observed. A recent analysis of
FACETS trial data dividing male patients in two sub-
groups (“classic phenotype” and “other patients”) showed
that migalastat led to reductions in LVMi in both sub-
groups. In particular change from baseline to month 24in LVMi was − 16.7 (SD 18.64) g/m2 (95% CI: − 31.1 to
− 2.4; n = 9) in males with the classic phenotype and −
3.2 (18.66) g/m2 (95% CI: − 12.5–6.1; n = 18) in other
patients [24]. In the ATTRACT trial, LVMi was signifi-
cantly decreased from baseline at month 18 with migala-
stat (− 6.6 g/m2; 95% CI: − 11.0 to − 2.2) but not with
ERT (− 2.0 g/m2; 95% CI: − 11.0–7.0) [15]. The largest
LVMi changes with migalastat were observed in the sub-
group of patients presenting baseline LVH.
On this basis, male and female patients aged ≥16
years with cardiac signs/symptoms of FD consisting
of electrocardiographic [32] and/or echocardiographic
and cardiac MRI evidence of LVH [5] and/or rhythm
(brady and/or tachyarrhythmias) and ECG alterations (PQ
interval < 120ms, atrioventricular block, sinus node
dysfunction, intraventricular conduction delay) [33] can
be considered for the treatment with migalastat.
Nevertheless, up to now there is no evidence that
treatment with migalastat may affect ECG alterations and
arrhythmic manifestation of FD. Indeed, as myocardial
fibrosis appears to be the major contributor of cardiac
arrhythmias, it is unlikely that both ERT and migalastat
will be effective in their treatment.Patients with renal involvement
Treatment with migalastat can be considered in patients with FD aged
≥16 years with amenable mutations and persistent microalbuminuria,
and/or proteinuria and/or eGFR> 30–90ml/min/1.73m2.Renal manifestations of FD occur early in life and if
not treated progress to end-stage renal disease in nearly
all male patients and some female patients [34]. Protein-
uria is strongly associated with renal disease progression.
Indeed, renal complications are key contributors to the
morbidity and mortality associated with FD. In routine
clinical practice, proteinuria and microalbuminuria are
considered the earliest signs of FD nephropathy [34, 35].
Renal biopsy remains the hall mark of FD nephropathy,
as significant GB3 accumulation has been found in several
types of kidney cells especially in the podocytes, even in
patients without overt signs of clinical kidney disease.
An important finding was the detection of early
segmental podocyte foot process effacement in most
normoalbuminuric young classic FD patients [36].
The assessment of renal function that should be
carried out includes serum creatinine, cystatin C, eGFR
estimated glomerular filtration rate, total urinary
protein excretion and urinary albumin excretion. The
utility of urine protein/creatinine ratios and eGFR has
been established for the staging of chronic kidney
disease [37].
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pathology, early diagnosis and timely initiation of treatment
at a young age are crucial, with the aim to slow down or
even reverse glomerular and vascular damage before
albuminuria or changes in GFR become overt [38].
Treatment recommendations for FD nephropathy
aim at controlling proteinuria to < 0.5 g/day and blood
pressure, and at initiating therapy promptly when evidence
of kidney involvement occurs. Patients who develop kidney
failure should undergo renal replacement therapy (dialysis
or kidney transplantation). Angiotensin-converting enzyme
inhibitors or angiotensin receptor blockers to reduce pro-
teinuria are also recommended [23].
It is known that GFR constantly declines in patients
with FD. Mehta et al. observed a mean yearly decline
of − 2.46 − 3.58 ml/min/1.73 m2 with ERT compared to
the yearly GFR decline of − 1 ml/min/1.7 3 m2 in the
normal adult population [39, 40].
The potential role of migalastat in the treatment of FD
nephropathy has been assessed in two trials. Firstly, in
the phase III, double-blind trial comparing migalastat
with placebo in ERT-naïve patients with migalastat-
amenable mutations (FACETS; n = 67), which showed a
statistically significant and durable reduction in GL-3 in-
clusions (proportion of patients with ≥50% reduction in
the average number of GL-3 inclusions per interstitial
capillary) in favor of migalastat when the analysis in-
cluded only patients with amenable mutations (mITT
population) [17]. In a separate analysis of eight males
with amenable mutations enrolled in the FACETS study
and for whom paired renal biopsies were available, miga-
lastat was associated with reductions from baseline in
mean total volume of GL-3 inclusions per podocyte and
mean podocyte volume after 6 months’ treatment [40].
No decrease of renal function was also observed with
migalastat during the FACETS trial, with an annualized
mean (±SE) change in eGFR from baseline to month 24:
− 0.30 ± 0.66 ml/min/1.73 m2). On the other hand, there
were no significant differences in baseline levels or
changes from baseline between study groups for 24-h
urinary protein excretion [17].
Secondly, the phase III open-label study (ATTRACT;
n = 60), demonstrated that migalastat was comparable to
ERT (either agalsidase alfa or agalsidase beta) with
respect to effects on renal function (annualized changes
in GFR from baseline through month 18) in ERT-
experienced patients with migalastat-amenable muta-
tions. In addition, the annualized rates of change in
eGFR among this group decreased less than the eGFR of
historic untreated patients regardless of the baseline
levels of urinary protein excretion [15, 41].
In a recent analysis in the subgroup of patients with
the classic phenotype treated with migalastat in the
FACETS trial, the annualized change in eGFR ChronicKidney Disease Epidemiology Collaboration (CKD-EPI)
was − 0.3 ml/min/1.73 m2 compared to historical studies
of untreated males reporting an annualized change in
eGFR of up to − 12.2 mL/min/1.73m2 [24].
A real-life study by Müntze et al., showed a decline in
renal function in some patients treated with migalastat.
The observation period of only one year after starting
chaperone treatment may have been too short to detect
a stabilization of the renal function that might require a
longer period [25]. In addition, the Authors report that
some patients started migalastat and ACE inhibitors or
AT1 receptor inhibitors at the same time, thus poten-
tially influencing the GFR reduction independently of
the chaperone therapy.
Thus, at the time this overview was written,
available data showed that migalastat did not change
the renal function decline induced by Fabry disease,
in the observation period covered by published
studies [15, 17, 24, 25, 40, 41].
Migalastat in patients with neurological involvement
Treatment with migalastat can be considered in patients with FD aged
≥16 years with amenable mutations and transient ischemic attack
/stroke and/or white matter lesions.The first neurological symptoms of FD usually occur
in the peripheral nervous system (PNS) as a result of
neuronal damage, which contributes to the onset of
neuropathic pain, dysesthesias, and sensory deficits,
including hearing loss [4]. In the central nervous
system (CNS), ischemic stroke and transient ischemic
attacks are the most prevalent cerebrovascular
complications of FD. The majority of strokes are of
lacunar type and mainly due to GL-3 accumulation in
the endothelium of small intracranial vessels [42].
Nevertheless, asymptomatic cerebral white matter
hyperintensities represent the most common, although
aspecific, expression of cerebral involvement in this
condition, with a prevalence up to 80% of the cases.
Progression of white matter lesions was seen during
follow-up irrespective of gender and ERT treatment
[43]. The pathophysiology of white matter lesions in
FD is complex and not well established; however,
these abnormalities seem to be related to stroke, cere-
bral small vessel dysfunction, cognitive impairment,
and motor abnormalities [42, 44].
Since migalastat is able to cross the blood–brain
barrier, it might contribute in reducing the occurrence
of cerebrovascular events and of white matter lesion
load [45]. However, in the phase III ATTRACT study,
the low proportion of patients with cerebrovascular
events (one in the ERT group and none with migalastat)
Chimenti et al. Orphanet Journal of Rare Diseases           (2020) 15:86 Page 8 of 10does not allow to get any firm conclusion [15].
Further studies including a larger population of FD
patients with cerebrovascular diseases and/or white
matter lesions are necessary to assess the potential
relevance of the drug in limiting the progression of
neuronal damage.
Migalastat in patients with other symptoms
Treatment with migalastat can be considered in patients with FD aged
≥16 years with amenable mutations with acroparaesthesia, and/or
gastrointestinal symptoms, and/or hearing loss.Neuropathic pain (also called acroparesthesia) is
one of the earliest symptoms and is present in
approximately 70% of young FD patients with classic
phenotype [46]. Hypoidrosis and heat/cold intolerance
with pain crises are frequently reported with a
negative effect on patients’ quality of life. Neuropathic
pain is probably related to progressive reduction in
the density of small myelinated and unmyelinated C
fibers in the peripheral somatic and autonomic
nervous system, while hypohidrosis is mainly due to
both small fiber neuropathy and sweat gland tubules
GL3 deposits [21]. Some studies suggest a benefit of
ERT on neuropathic pain [47–50]. In Phase III
ATTRACT study, patients in migalastat group or in
ERT group had stable and comparable scores on the
Brief Pain Inventory-Short Form during the study
period [15].. Clinical evidence for an improvement of
acroparesthesiae and hearing loss is still wanted.
Gastrointestinal symptoms are some of the earliest
and most frequent symptoms of FD, being reported
in approximately 60 and 50% of children and adults,
respectively; they include abdominal pain, bloating,
diarrhea, constipation, nausea and vomiting, and are
associated with a major worsening of quality of life
[4]. In the FACETS trial, migalastat-treated patients
demonstrated decreased gastrointestinal symptoms for
diarrhea, reflux and indigestion per the Gastrointes-
tinal Symptom Rating Scale [17].
In a subanalysis of the FACETS trial, minimal
clinically important differences (MCID) in diarrhea
based on the corresponding domain of the patient-
reported Gastrointestinal Symptom Rating Scale (GSRS)
were evaluated [51]. After 6 months’ treatment, more pa-
tients receiving migalastat experienced improvement in
diarrhea based on a MCID of 0.33, compared with pla-
cebo recipients (43% vs 11%; p = 0.02). These findings
were consistent also in patients with baseline diarrhea
(71% vs 20%; p = 0.02).
FD-associated hearing loss can be progressive or
sudden [4], and can be due to different reasons [4].Hearing loss has been reported in 18–55% of FD
patients, and tinnitus in 17–53% [4]. It is important
to understand the cause of any hearing impairment
prior to treatment initiation; audiometry testing and
neurological investigations should therefore be
performed at diagnosis and then at regular intervals.
Migalastat in patients with ERT failure/intolerance
In a patient aged ≥16 years with amenable mutation already in
treatment with ERT, switching to migalastat should be considered in the
case of poor response and/or uncontrolled infusion reactions and/or
poor compliance to intravenous therapy.In the opinion of Authors, and based on the results of
the ATTRACT study, given the possibility of oral therapy
and its efficacy and safety, switching to migalastat can be
considered in: (i) unstable patients with clinical evidence
of progression of FD, in particular GI symptoms,
cardiac hypertrophy and CNS events, (ii) patients with
uncontrolled infusion reactions, (iii) patients with oor
compliance to i.v. chronic infusions, as shown in the
ATTRACT trial [15, 52].
Conclusions
Although studies and data on longer-term follow up
with migalastat are still emerging, available evidence is
consistent in showing that this molecule does represent
a suitable therapy for the treatment of FD, in patients
aged ≥16 years and with amenable mutations and eGFR
30–90ml/min/1.73 m2. The use of migalastat as an oral
option appears to be overall safe, and experience thus
far indicates potential for improving quality of life, con-
trolling GI symptoms, stabilizing renal function and re-
ducing cardiac hypertrophy.
Migalastat can be considered either as a first-line ther-
apy – given its efficacy, extensive tissue penetration,
convenient oral regimen, and the current limited thera-
peutic options available – or in patients on ERT who
experience side effects, poor compliance to chronic i.v.
therapy, or in the case of unstable disease. It should be
noted that, until data on longer-term follow up are ac-
quired, careful monitoring of patients treated with miga-
lastat is warranted. Increasing real life clinical use, with
increasing number of patients closely followed-up for
prolonged periods, will be crucial to gain more experi-
ence on migalastat in daily practice.
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